कृपया अन्य खोज का प्रयास करें
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. The company was incorporated in 2012 and is headquartered in New York, New York.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Joshua N. Silverman | 51 | 2016 | Independent Chairman of the Board |
William S. Singer | 80 | 2013 | Independent Vice-Chairman of the Board |
Daniel L. Alkon | 79 | 2020 | President, Chief Scientific Officer & Director |
Paul Coleman | - | - | Member of Scientific Advisory Board |
Alan J. Tuchman | 74 | 2020 | CEO & Director |
Jonathan L. Schechter | 47 | 2018 | Independent Director |
Lee Jen Wei | - | - | Member of Scientific Advisory Board |
Daniel F. Hanley | 72 | - | Member of Scientific Advisory Board |
Marwan Noel Sabbagh | - | - | Member of Scientific Advisory Board |
Martin Rhys Farlow | - | - | Member of Scientific Advisory Board |
George Perry | 68 | 2017 | Chairman of the Scientific Advisory Board |
Bruce T. Bernstein | 58 | 2016 | Independent Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है